Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.56 |
| ▸ | TLR2 | O60603 | 1/20 | 0.53 |
| ▸ | NMT1 | P30419 | 5/20 | 0.52 |
| ▸ | NMT2 | O60551 | 4/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19696608 | 0.95 | SLC6A5 (0.50) | SLC6A5TLR2NMT1NMT2ROCK2 | |
| SCHEMBL17955254 | 0.95 | SLC6A5 (0.50) | SLC6A5TLR2NMT1NMT2ROCK2 | |
| SCHEMBL9664106 | 0.92 | SLC6A5 (0.67) | SLC6A5TLR2NMT1NMT2NOD1 | |
| SCHEMBL9664216 | 0.92 | SLC6A5 (0.67) | SLC6A5TLR2NMT1NMT2NOD1 | |
| SCHEMBL12640054 | 0.92 | SLC6A5 (0.67) | SLC6A5TLR2NMT1NMT2NOD1 | |
| SCHEMBL5693676 | 0.92 | SLC6A5 (0.67) | SLC6A5TLR2NMT1NMT2NOD1 | |
| SCHEMBL9666267 | 0.92 | SLC6A5 (0.67) | SLC6A5TLR2NMT1NMT2NOD1 | |
| SCHEMBL18735588 | 0.92 | SLC6A5 (0.67) | SLC6A5TLR2NMT1NMT2NOD1 | |
| SCHEMBL22821587 | 0.92 | SLC6A5 (0.67) | SLC6A5TLR2NMT1NMT2NOD1 | |
| SCHEMBL15185893 | 0.91 | SLC6A5 (0.48) | SLC6A5TLR2NMT1NMT2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022271818-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | ENTRADA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20210139539-A1 | NEW ANTIBACTERIAL PRODUCTS | THE UNIVERSITY OF LIVERPOOL (GB) | 2021-05-13 | — | — | US | disclosed |
| US-9096646-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130210709-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-08-15 | — | — | US | disclosed |
| WO-2010053548-A2 | PTHR1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139539-A1 | NEW ANTIBACTERIAL PRODUCTS | DBI, MRPL21, NRDC | SLC6A5 3444/4885TLR2 305/4885NMT1 1313/4885 |
| US-20130210709-A1 | CXCR4 Receptor Compounds | CXCR4, CXCL12, SDF4 | SLC6A5 3188/4885TLR2 886/4885NMT1 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.